Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 8Lung Neoplasms 6Colorectal Neoplasms 6Neoplasms 5Prostatic Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Ovarian Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liver Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaccinia 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Papillary renal cell carcinoma, sporadic 1PIK3CA-Mutated Cancers 1Osteosarcoma 1

Interventions

lutetium Lu 177 dotatate 1atezolizumab 1Etoposide 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × atezolizumab × 30 days × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡